Abstract
Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Current Drug Discovery Technologies
Title:A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines
Volume: 10 Issue: 4
Author(s): Miliana Vojvodic, Loen M. Hansford, Olena Morozova, Kim M. Blakely, Paul Taylor, Kelly E. Fathers, Jason Moffat, Marco Marra, Kristen M. Smith, Michael F. Moran and David R. Kaplan
Affiliation:
Keywords: Bosutinib, BMS-354825, dasatinib, kinase inhibitors, phosphoproteomics, SKI-606, Src family kinases.
Abstract: Mass spectrometry-based technologies are increasingly utilized in drug discovery. Phosphoproteomics in particular has allowed for the efficient surveying of phosphotyrosine signaling pathways involved in various diseases states, most prominently in cancer. We describe a phosphotyrosine-based proteomics screening approach to identify signaling pathways and tyrosine kinase inhibitor targets in highly tumorigenic human lymphoma-like primary cells. We identified several receptor tyrosine kinase pathways and validated SRC family kinases (SFKs) as potential drug targets for targeted selection of small molecule inhibitors. BMS-354825 (dasatinib) and SKI-606 (bosutinib), second and third generation clinical SFK/ABL inhibitors, were found to be potent cytotoxic agents against tumorigenic cells with low toxicity to normal pediatric stem cells. Both SFK inhibitors reduced ERK1/2 and AKT phosphorylation and induced apoptosis. This study supports the adaptation of high-end mass spectrometry techniques for the efficient identification of candidate tyrosine kinases as novel therapeutic targets in primary cancer cell lines.
Export Options
About this article
Cite this article as:
Vojvodic Miliana, Hansford M. Loen, Morozova Olena, Blakely M. Kim, Taylor Paul, Fathers E. Kelly, Moffat Jason, Marra Marco, Smith M. Kristen, Moran F. Michael and Kaplan R. David, A Phosphoproteomics Approach to Identify Candidate Kinase Inhibitor Pathway Targets in Lymphoma-Like Primary Cell Lines, Current Drug Discovery Technologies 2013; 10 (4) . https://dx.doi.org/10.2174/15701638113109990001
DOI https://dx.doi.org/10.2174/15701638113109990001 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Infectious Complications with Anti-TNFα Therapy in Rheumatic Diseases: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry STAT Inhibition in the Treatment of Cancer: Transcription Factors as Targets for Molecular Therapy
Current Cancer Therapy Reviews The Glioblastoma Problem: Targeting by Combined Medicinal Chemistry Approaches
Current Medicinal Chemistry Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
Current Cancer Drug Targets Inflammation and Anemia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial: Stress and Gastrointestinal Tract: Physiology, Pathophysiology, Pathology and Pharmacology
Current Pharmaceutical Design Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Gene Polymorphisms and Pharmacogenetics in Rheumatoid Arthritis
Current Genomics The Immune System of Cancer Patients
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vitiligo: An Updated Narrative Review
Current Pediatric Reviews Strategies for the Biological Evaluation of Gold Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry The Role of Sigma-1 Receptor, an Intracellular Chaperone in Neurodegenerative Diseases
Current Neuropharmacology Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Respiratory Failure in Cancer Patients: Non-Infectious Complications of Antineoplastic Agents for Solid Tumors
Current Respiratory Medicine Reviews Understanding Mesenchymal Cancer: The Liposarcoma-Associated t(12;16) (q13;;p11) Chromosomal Translocation as a Model
Current Genomics Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry